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Mycotic aortic aneurysms are rare in this age of
antibiotic therapy. However, they still present a
pathologic entity with high morbidity and mortality
rates. We report on in situ replacement of mycotic
aortic aneurysm with a cryopreserved aortic allo-
graft in a case of chronic pancreatitis that was com-
plicated by infected pancreatic pseudocysts and
retroperitoneal abscess.
CASE REPORT
A 53-year-old man was admitted to the hospital with a
suspected abdominal aortic aneurysm. Twelve years earlier
he underwent the Whipple procedure for alcohol-induced
chronic pancreatitis, and 2 years later he underwent exci-
sion of a pancreatic pseudocyst. During the following 4
years recurrent pancreatico-cutaneous fistulas necessitated
multiple surgical revisions, which were finally closed by
endoblockade with fibrin sealant.
On admission, physical examination revealed mild upper
abdominal tenderness and a pulsatile midabdominal mass.
The patient was pyrexial at 39°C, and his white blood cell
count showed a leukocytosis of 32.000/mm3. An abdomi-
nal computed tomography (CT) scan showed multiple pan-
creatic pseudocysts that compressed the infrarenal aorta (Fig
1). An aneurysm had developed distal to the stenosis and was
surrounded by a retroperitoneal abscess (Fig 2). Angi-
ography confirmed the aortic compression (arrow in Fig 2)
and a mycotic aneurysm in the lower infrarenal aorta.
The patient underwent emergency surgery. Explor-
ation showed an erosion of the infrarenal aorta by infect-
ed pancreatic pseudocysts, which contained a seropurulent
exudate. These and the mycotic aneurysm were resected,
the periaortic infected tissues were carefully debrided to
obtain macroscopically normal tissues, and the aorta was
replaced in situ with a cyropreserved aortic allograft with
a 10-cm length. The allograft, which was matched for
blood type, was provided by our own tissue bank, which is
associated with the foundation Bio Implant Services in
Leiden, The Netherlands. The technique of cryopreserva-
tion has been described previously.1 The allografts were
harvested from multiorgan donations. Graft preparation
included sterile procurement and storage at 4°C in a
preservation fluid with antibiotics according to the
method of Yankah and Hetzer.2 In brief, within 24 hours
of storage, the allografts were placed in a fresh antibiotic
and antimycotic medium (flucytosin 1.5 mg/mL, van-
comycin 0.6 mg/mL, amikacin 0.6 mg/mL, ciprofloxacin
0.15 mg/mL, and metronidazol 0.6 mg/mL) supple-
mented with 10% dimethyl sulfoxide (Fisher Scientific Co,
Pittsburgh, Pa.). The grafts were then cryopreserved in a
computer-controlled rate freezer that lowered the temper-
ature 1°C per minute down to a temperature of –40°C.
The specimens were then placed in the vapor phase of a
liquid nitrogen freezer.
Intraoperative cultures from the seropurulent exudate
and specimens of the resected aortic wall grew Salmonella
enteritidis. The patient received high-dose intravenous antibi-
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otics (1 g ampicillin four times a day) for 6 weeks postopera-
tively according to sensitivities. The effectiveness of the
antibiotic therapy was ascertained by C-reactive protein levels.
The patient made an uneventful recovery and 31
months later is still well. Follow-up angiography (Fig 3)
and CT scans, which are performed in 6-month intervals,
show no signs of recurrent infection.
DISCUSSION
Vascular erosion and massive hemorrhage remain
the most dreaded complications that arise from pan-
creatic pseudocysts. Typically, pseudocyst hemorrhage
results from vessels in the cyst wall or from erosion of
the splenic or gastroduodenal arteries.3 Erosions of
the aorta by pancreatic pseudocysts are quite rare.4
We report a case of chronic pancreatitis with infected
Fig 3. Follow-up digital subtraction arteriogram of the
abdominal aorta shows an intact abdominal aorta of normal
size without any sign of recurrent aneurysm formation.
Fig 1. Abdominal CT scan with contrast enhancement shows multiple pancreatic pseudocysts
(P) compressing the infrarenal aorta.
Fig 2. Digital subtraction arteriogram of the abdominal
aorta revealed an aortic compression (arrow) and a large
mycotic aneurysm in the lower infrarenal aorta.
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pseudocysts that was complicated by aortic erosion
and large mycotic aneurysm formation of the
infrarenal aorta. Differential pathophysiologic factors
that might be the source of aneurysm formation are
(1) erosion by an expanding pseudocyst, (2) local
infection, (3) autodigestion by pancreatic enzymes,
and (4) bacteremic embolization of the vasa vasorum.
Intraoperative cultures of the presented case grew S
enteritidis, which is known as one of the most com-
mon pathogens of mycotic aneurysm formation.5
The optimal surgical management of mycotic aor-
tic aneurysm remains controversial. The standard
treatment consists of the administration of high-dose
organism-specific parenteral antibiotics, prompt exci-
sion of all infected tissue, and reconstruction with
extra-anatomic bypass graft. However, dissatisfaction
with extra-anatomic techniques has led to the devel-
opment of approaches of in situ replacement with
prosthetic,6 autogenous,7-12 or allograft material13-19
to avoid complications related to aortic stump disease
and subsequent infection and occlusion of extra-
anatomic bypass grafts.
Cryopreserved aortic allografts have been proved
to be both experimentally and clinically resistant to
bacterial contamination.1,14-20 As previously report-
ed, they have an intrinsic resistance to infection
when compared with prosthetic grafts, which is opti-
mized by antibiotic loading during the cryopreser-
vation process.20
In this case, the antibiotic treatment of the allo-
graft was performed according to the protocol used
by the foundation Bio Implant Services using van-
comycin and amikacin. The isolated strain was high-
ly sensitive to vancomycin and amikacin, and the
concentration of these antibiotics in the decontami-
nating solution was very high. The antibiotics may
then have been carried over in the tissues surround-
ing the allograft after implantation and may have
contributed to the therapeutic effects of the systemic
antibiotic treatment.
To date, there have been 129 cases in published
series of in situ replacement with cryopreserved aor-
tic allografts for aortic infections.1,14-19 On the basis
of a mean follow-up period of 13.8 months (1
month–5 years), the perioperative mortality was
13.2% (5.2%-22.2%). The rate of reinfection was
6.2% (0%-12.9%), and the incidence of late amputa-
tions was 3.3% (0%–7.4%). Our own experience,
even in cases of high-risk immunosuppressed
patients, has been very satisfactory, not only with
regard to the hospital and midterm survival rate, but
also with regard to shortened hospitalization and a
reduction of antibiotic requirements.1
We therefore continue to use vascular allografts as
the conduit of choice in the surgical treatment of
mycotic aneurysms and infected prosthetic grafts. We
advocate the harvesting of the entire aorta during mul-
tiorgan donation for cryopreservation because mycotic
aneurysms are usually ruptured when diagnosed.
Although it has been shown that immunosuppres-
sive treatment may increase arterial allograft patency
and prevent aneurysmal degeneration,21 this was not
considered feasible under the infective conditions of
mycotic aneurysms. However, as opposed to other
studies, the allograft in this report was matched for
blood type. Autogenous superficial femoropopliteal
vein reconstruction is another option for in situ recon-
struction in the presence of aortofemoral infections.8-
12 The main advantages of this approach seem to be
the good resistance to reinfection and the availability
of the grafts. So far there have been 90 reported cases
with a mean follow-up of 24.8 months (2-60 months)
and no recurrent infections. The mean in-hospital
mortality was 11.1% (6.7%-20%), and the amputation
rate was 11.1% (0%-23.5%). However, a substantial
number of patients experienced significant morbidity
that included complications that were directly related
to the features of the procedure: compartment syn-
drome in 7.8% (0%-12.2%), lower extremity paresis or
paralysis in association with prolonged ischemia in
4.4% (0%-10%), and deep venous thrombosis in 7.8%
(0%-14.6%). Nevertheless, it is difficult to compare the
series of cryopreserved arterial allografts and superficial
femoropopliteal veins directly because of a broad het-
erogeneity in terms of severity of presenting problems,
associated comorbidities, infecting organisms, and the
completeness of reporting. Therefore, long-term fol-
low-up and larger numbers will be necessary to com-
pare both of these techniques. 
In conclusion, mycotic aneurysm of the infrarenal
aorta is an uncommon complication of chronic pancre-
atitis. The keystones in successful management of these
cases are early recognition of the aneurysm, immediate
appropriate surgical treatment, immediate administra-
tion of infection-specific parenteral antibiotics for at
least 4 to 6 weeks, and close follow-up monitoring. The
use of cryopreserved aortic allografts is a promising and
effective operative concept for arterial in situ recon-
struction in a grossly infected field.
We are grateful for editorial assistance from Tonie
Derwent.
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